PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “SARCOMA, LYMPHOSARCOMA”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed1985

[Cisplatin for malignant lymphoma--preliminary observation on 43 patients].

This paper reports the treatment results of cisplatin in 43 cases of malignant lymphoma. All were proved by pathology, cytology or X-ray and were non-resectable, disseminated advanced or refractory to routine anticancer drugs. The total dose of each course of cisplatin was usually 100-150 mg (2 mg/kg). One fifth or a tenth part of the dose was given with normal saline intravenously once a day. Complete remission rate was 9%, partial remission rate was 28%. Lymphosarcoma and reticulum cell sarcoma gave better results. During the treatment, anorexia, nausea and vomiting were common. Mild or moderate reduction of WBC and platelet was usually observed in the partial responsive cases but the depression on the bone marrow was relative mild. Cisplatin therapy did not cause marked renal dysfunction which was probably due to the hydration instituted. The anticancer action of cisplatin is similar to that of the alkylating agents but the participation of immunologic mechanism may also play a role.

Adult↗
PubMed1977

[Study of the toxicity and antiblastoma activity of antibiotics echinomycin and 6270 in complexes with DNA].

Studies with the use of intact inbred albino mice showed that in intravenous administration the acute toxicity of antibiotic No. 6270 and echinomycin in complexes with DNA increased 3--4 times as compared to the toxicity of the same antibiotics used without the complex. Under the experimental conditions with 3-fold intravenous administration at 72-hour intervals in doses equivalent by their acute toxicity, the antitumor activity of the echinomycin complex with DNA against the solid form of lymphosarcoma L10-1 was approximately 4 times lower than the activity of the antibiotic used alone. Like echinomycin, antibiotic No. 6270 in complex with DNA used according to the same administration scheme in doses equivalent by their acute toxicity had a lower inhibitory effect on growth of lymphosarcoma L10-1 and sarcoma 180 as compared to its use alone.

Animals↗
PubMed1996

[Superoxide-producing lipoprotein as a tumor growth suppressing factor, increasing the number of leukocytes and accelerating cell division in culture].

Superoxide-generating lipoprotein was isolated and purified from human serum; four intraperitoneal injections of Fe(3+)-activated suprol (150 micrograms/ml) increased rat peripheral blood leukocytes only by 8-10% in 24 h. In 3 days after inoculation of animals with Pliss lymphosarcoma or M-1 sarcoma, similar injections of activated suprol increased leukocyte count up to the numbers in healthy animals. Growth of M-1 sarcoma and Pliss sarcoma was decreased by 31 +/- 4 and 52 +/- 2%, respectively. Activated suprol (15 micrograms/ml) stimulated growth of stationary chicken embryonic cell culture by 52.1%. Activated suprol at concentrations exceeding 50 micrograms/ml lysed all cells in the culture. Cu,Zn-superoxide dismutase suppressed suprol-stimulated proliferation of actively proliferating culture; not activated (native) suprol did not significantly increase leukocyte count, did not suppress tumor growth, and did not stimulate growth of cultured cells. The data suggest an important role of superoxide radicals in these processes. Inhibition of tumor growth by suprol may be associated with tumor DNA degradation by superoxide radicals (tumor DNA is more sensitive to O2- because superoxide dismutase activity is significantly lower in tumor cells versus normal tissues) and increased resistance of the organism due to stimulation of leukopoiesis.

Animals↗
PubMedDate not supplied

Classification of feline intraocular neoplasms based on morphology, histochemical staining, and immunohistochemical labeling.

The objectives of this study were to evaluate morphologic, histochemical, and immunohistochemical characteristics of well-differentiated and anaplastic intraocular neoplasms of cats, and to develop a diagnostic algorithm for, and investigate the association of ruptured lenses with these neoplasms. Seventy-five feline globes with intraocular neoplasms were stained with hematoxylin and eosin and examined by light microscopy. Morphologic diagnoses included 33 intraocular sarcomas, 17 diffuse iris melanomas, 15 lymphosarcomas, three ciliary adenomas, one metastatic carcinoma, and six undifferentiated intraocular neoplasms. Sections of these globes were then stained with periodic acid Schiff (PAS), and immunohistochemical (IHC) labels for various cellular markers. Histochemical staining and IHC labeling confirmed cellular differentiation in 73/75 neoplasms but was discordant with morphologic diagnoses in 8/75. These included four neoplasms morphologically diagnosed as lymphosarcomas but which expressed differentiation antigens consistent with melanoma (n = 3) or ciliary adenocarcinoma (n = 1), and four tumors morphologically diagnosed as intraocular sarcomas that expressed differentiation antigens for melanoma (n = 2), metastatic carcinoma (n = 1), or remained undifferentiated (n = 1). Immunohistochemical labeling suggested a diagnosis in 5/6 morphologically undifferentiated neoplasms including one intraocular sarcoma, two diffuse iridal melanomas, and two ciliary adenocarcinomas. Based upon morphologic, histochemical, and IHC characterization, ruptured lens capsules were detected in 28/30 intraocular sarcomas, 3/24 diffuse iris melanomas and 1/11 lymphosarcomas, but not in ciliary epithelial neoplasms, metastatic carcinomas, or undifferentiated intraocular neoplasms. An algorithm is provided that facilitates stain and IHC label selection for differentiating anaplastic intraocular feline neoplasms.

Adenoma↗
PubMed1983

The effect of histidine ammonia-lyase on some murine tumours.

The histidine ammonia-lyase from bacterial strain CAMR 5315 was partially purified to assess its effect on the growth of murine tumours. This strain was selected as the source after an extensive screening programme for histidine ammonia-lyases. The enzyme was partially purified by ammonium sulphate fractionation, chromatography on DEAE-cellulose and Sephadex G-150. The enzyme reduced circulating L-histidine levels in Wistar rats and in mice persisted with a half-life of 6-7 h. Neither LDH virus nor chemical modification with ethylacetimidate increased the half-life as observed with L-asparaginase and L-glutaminase. The enzyme was tested in mice against Ehrlich carcinoma, L5178Y lymphoblastic leukaemia, Mc/S sarcoma, B16 melanoma, P8157 mastocytoma, P1798 lymphosarcoma and the Gardner 6C3HED lymphosarcoma. The only tumours to show sensitivity to the enzyme were the Mc/S sarcoma against which a 65% increase in life span was observed at the highest enzyme dose, 1000 U/kg on alternate days over 14 days and the Ehrlich ascites carcinoma where cures were obtained at 250 U/kg on alternate days over 14 days, but only at inocula levels of 10(5) and 10(3) cells/animal respectively.

Ammonia-Lyases↗
PubMed1975

Lymphomas: initial reactivation.

A total of 299 patients with Stage IA-Stage IIB nodal lymphoma treated by irradiation were evaluated for initial reactivation. The abdomen was the major site of reactivation for patients with supradiaphragmatic Hodgkin's disease. The non-Hodgkin's lymphomas reactivated in a variable fashion. Reactivation was prompt for patients with reticulum-cell sarcoma and longer for patients with other lymphomas. Initial extranodal manifestations were present in 24%, 51%, and 63% of patients with Hodgkin's disease, lymphosarcoma, and reticulum-cell sarcoma, respectively.

Abdominal Neoplasms↗
PubMed1979

Study of malignant lymphomas from the aspect of immunoglobulin production.

Intracytoplasmic localization of immunoglobulins in neoplastic cells of malignant lymphomas was studied by both light and electron microscopic immunoperoxidase methods. This was demonstrated in 17 out of 71 cases submitted to light or electron microscopic immunoperoxidase methods. Out of 19 cases examined by the electron microscopic immunoperoxidase method, immunoglobulins were intracellularly identified in 10 cases; 3 out of 6 cases which were diagnosed as follicular lymphoma, 3 out of 5 cases of reticulosarcoma, 2 out of 6 cases of lymphosarcoma and 2 cases of immunoblastic sarcoma. Out of the above 10 cases, IgM was demonstrated in 9 cases except one of immunoblastic sarcoma in which IgA, IgG and IgM were identified intracellularly. In addition to these findings, our ultracytological and pathological studies have indicated that immunoglobulin-producing tumors can be classified into the following three major groups according to their cellular origin; germinal centers (group 1), primary follicles (group 2) and extrafollicular (group 3). Group 1 is comprised of follicular lymphoma and reticulosarcoma, group 2 lymphosarcoma, and group 3 immunoblastic sarcoma.

Adolescent↗